Clinical Trials · NCT07842640
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Ascletis Pharma (China) Co., Limited
- Enrollment
- 84
- Start date
- Aug 2026
- Locations
- 1 site, United States
- Primary endpoint
- Adverse events